跳至主要内容
临床试验/NCT02169817
NCT02169817已完成4 期

Bacillus Clausii in the Treatment of Acute Community-acquired Diarrhea Among Latin American Children (cadiLAc)

Sanofi11 个研究点 分布在 5 个国家目标入组 629 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
629
试验地点
11
主要终点
Duration of diarrhea-from the date and time of first intake of investigational product up to date and time of first appearance of a loose stool followed by two consecutive normal stools recorded in the patient diary

研究概览

简要总结

Primary Objective:

To demonstrate the effectiveness of treatment with Bacillus clausii probiotic strain (Enterogermina) in combination with oral rehydration therapy (ORT) for a period of 5 days, in the duration of acute community-acquired diarrhea in Latin American children.

Secondary Objectives:

To evaluate the clinical safety of Enterogermina in acute diarrhea in children and to demonstrate its effectiveness on stool frequency, stool consistency, and number of vomiting episodes.

To evaluate parent's overall global assessment. To evaluate the safety and effectiveness of Enterogermina in norovirus acute gastroenteritis (AGE).

详细描述

The maximum duration of study participation for each patient can be 10 days.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Enterogermina + Enterolyte

Experimental

2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation

干预措施: Bacillus clausii (Drug)

Enterogermina + Enterolyte

Experimental

2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation

干预措施: Oral Rehydration Therapy (Drug)

结局指标

主要结局

Duration of diarrhea-from the date and time of first intake of investigational product up to date and time of first appearance of a loose stool followed by two consecutive normal stools recorded in the patient diary

时间窗: from Day 1 to Day 5

次要结局

  • Parent / Legal guardian's assessment of children's overall acceptance of Enterogermina(Day 1 to Day 5)
  • Parent / Legal guardian's assessment of children's overall general state(Day 1 to Day 5)
  • Effect on consistency of stool(Day 1 to Day 5)
  • Mean number of stools per day(Day 1 to Day 5)
  • Number of vomiting episodes per day(Day 1 to Day 5)
  • Safety outcome: Adverse events collection reported by the parent / legal guardian in diary and checked by the investigator(Day 1 to Day 5)

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验

Evaluation Of Bacillus Clausii In Treatment Of Acute... | 临床试验